Evan Lippman

CIK: 0002062834

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)3 (37.5%)

Position reduction

Option Exercises (M)2 (25.0%)

Derivative conversions

Awards (A)3 (37.5%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

TEVA

TEVA PHARMACEUTICAL INDUSTRIES LTD

Officer

Discretionary Trading P&L

Holdings

Transaction History (8 total)

TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Aug 17, 2026
Sale(S)
Direct
18.6K shares at avg. $36.57$680K
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
May 14, 2026
Sale(S)
Direct
5.7K shares at avg. $35.58$204K
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
May 14, 2026
Exercise(M)
Direct
74K shares-
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
May 14, 2026
Sale(S)
Direct
35.9K shares at avg. $35.58$1.3M
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
May 14, 2026
Exercise(M)
Direct
11.8K shares-
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Mar 4, 2026
Award(A)
Restricted Share Units
Direct
27.3K shares-
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
May 14, 2025
Award(A)
Restricted Share Units
Direct
47.4K shares-
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
May 14, 2025
Award(A)
Restricted Share Units
Direct
148K shares-

		Type	Shares	Price		Ownership
Aug 17, 2026	TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD	Sale(S)	18,600	$36.57	$680,291	Direct
May 14, 2026	TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD	Sale(S)	5,746	$35.58	$204,467	Direct
May 14, 2026	TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD	Exercise(M)	74,008	-	$0	Direct
May 14, 2026	TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD	Sale(S)	35,912	$35.58	$1,277,900	Direct
May 14, 2026	TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD	Exercise(M)	11,841	-	$0	Direct
Mar 4, 2026	TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD	Award(A) Restricted Share Units	27,347	-	-	Direct
May 14, 2025	TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD	Award(A) Restricted Share Units	47,365	-	-	Direct
May 14, 2025	TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD	Award(A) Restricted Share Units	148,016	-	-	Direct

1-8 of 8 transactions

About Lippman Evan

Lippman Evan (SEC CIK 0002062834) files insider reports with the SEC as EVP, Business Development of TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA).

Signal8 holds 5 ownership filings by Lippman Evan (1 Form 3, 4 Form 4), filed between Apr 7, 2025 and Aug 19, 2026. Those filings report 8 transactions, from May 14, 2025 to Aug 17, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Lippman Evan's filings is in TEL AVIV.

Recent filings by Lippman Evan

Aug 17, 2026: Open-market sale of TEVA shares (Form 4, code S).
May 14, 2026: Open-market sale of TEVA shares (Form 4, code S).
May 14, 2026: Option exercise of TEVA shares (Form 4, code M).
May 14, 2026: Open-market sale of TEVA shares (Form 4, code S).
May 14, 2026: Option exercise of TEVA shares (Form 4, code M).

Other insiders filing for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Bergwerk Dov, Interim Cheif Legal Officer
Savage Brian, Interim Chief Legal Officer
MIGNONE ROBERTO, Director
Weiss Amir, Chief Accounting Officer
Satchi-Fainaro Ronit, Director
Zaks Tal Zvi, Director

How to read Form 4 transaction codes